Safety and efficiency of anti-angiogenesis combine with neoadjuvant chemo-radiotherapy in local advanced esophageal squamous cell carcinoma patients followed by esophagectomy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000031228

Enrollment

Unknown

Registered

2020-03-25

Start date

2020-04-01

Completion date

Unknown

Last updated

2020-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal carcinoma

Interventions

Experimental group:Anlotinib

Control group:Nil

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. patients with local advanced esophageal carcinoma(clinical stage T3a-T4); 2. patients without distance metastasis; 3. patients aged 18 to 75 years; 4. patients who were not participants in other clinical trials;5.patients who can tolerate the toxicity of the chemo-radiotherapy and have indications for surgery.

Exclusion criteria

Exclusion criteria: Patients who were participants in other clinical trials.

Design outcomes

Primary

Measure	Time frame
surgical rate;	—

Secondary

Measure	Time frame
clinical complete response rate;pathological complete response rate;toxicity;perioperative complication;disease-free survival rate;overall survival rate;	—

Countries

China

Contacts

Public ContactGuo Wei

Department of Thoracic Surgery, Medical Center of Amry Medical University

gyguowei@hotmail.com+86 13527323568

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026